Merk Announces Topline Results From Its Phase 3 ATLAS-UC Induction-Only Study Evaluating Tulisokibart In Patients With Moderately To Severely Active UC; Study Successfully Met Its Primary Endpoint Of Clinical Remission

Loading news article.

Merk Announces Topline Results From Its Phase 3 ATLAS-UC Induction-Only Study Evaluating Tulisokibart In Patients With Moderately To Severely Active UC; Study Successfully Met Its Primary Endpoint Of Clinical Remission | WAPE

Merk Announces Topline Results From Its Phase 3 ATLAS-UC Induction-Only Study Evaluating Tulisokibart In Patients With Moderately To Severely Active UC; Study Successfully Met Its Primary Endpoint Of Clinical Remission

Article summary

Related companies

Comments —